Table 1.
Change in gene expression (in order of significance) after lithium treatment (2 and 8 weeks combined and separately) in all bipolar subjects (n = 22) at FDR <0.1
| Gene symbol | Treated vs. untreated |
Treated 2 weeks vs. untreated |
Treated 8 weeks vs. untreated |
Gene title | ||||
|---|---|---|---|---|---|---|---|---|
| p value | FDR | fold change | p value | fold change | p value | fold change | ||
| CCDC19 | 4.91E–08 | 1.04E–03 | 1.21 | 1.90E–08 | 1.27 | 6.12E–05 | 1.16 | coiled-coil domain containing 19 |
| P2RY14 | 1.58E–07 | 1.67E–03 | 1.52 | 1.85E–05 | 1.46 | 3.97E–07 | 1.57 | purinergic receptor P2Y, G-protein coupled, 14 |
| IL5RA | 2.40E–07 | 1.69E–03 | 1.59 | 7.48E–06 | 1.58 | 2.13E–06 | 1.61 | interleukin 5 receptor, alpha |
| CNTNAP3 | 7.11E–07 | 2.70E–03 | 1.44 | 1.74E–06 | 1.51 | 6.09E–05 | 1.38 | contactin associated protein-like 3 |
| TSPAN2 | 8.46E–07 | 2.70E–03 | 1.45 | 7.64E–05 | 1.39 | 1.62E–06 | 1.50 | tetraspanin 2 |
| CPT1A | 8.81E–07 | 2.70E–03 | –1.32 | 1.96E–04 | –1.26 | 6.14E–07 | –1.38 | carnitine palmitoyltransferase 1A (liver) |
| ADORA3 | 1.21E–06 | 2.88E–03 | 1.27 | 1.06E–04 | 1.24 | 2.11E–06 | 1.30 | adenosine A3 receptor |
| IDO1 | 1.23E–06 | 2.88E–03 | 1.35 | 2.01E–05 | 1.35 | 1.28E–05 | 1.35 | indoleamine 2,3-dioxygenase 1 |
| MOK | 1.48E–06 | 3.12E–03 | 1.20 | 4.48E–06 | 1.23 | 8.08E–05 | 1.18 | MOK protein kinase |
| FAR2 | 2.38E–06 | 4.18E–03 | 1.34 | 3.77E–04 | 1.28 | 1.69E–06 | 1.41 | fatty acyl CoA reductase 2 |
| FGGY | 2.79E–06 | 4.53E–03 | –1.13 | 1.36E–04 | –1.12 | 6.96E–06 | –1.14 | FGGY carbohydrate kinase domain containing |
| CLC | 3.30E–06 | 4.97E–03 | 1.51 | 1.62E–05 | 1.56 | 8.60E–05 | 1.46 | Charcot-Leyden crystal protein |
| ALOX15 | 6.54E–06 | 7.44E–03 | 1.44 | 1.27E–04 | 1.43 | 3.26E–05 | 1.46 | arachidonate 15-lipoxygenase |
| MIR27A | 6.66E–06 | 7.44E–03 | 1.32 | 4.38E–05 | 1.34 | 1.02E–04 | 1.30 | microRNA 27a |
| CAMK1 | 7.32E–06 | 7.44E–03 | 1.16 | 2.73E–04 | 1.14 | 1.73E–05 | 1.17 | calcium/calmodulin-dependent protein kinase I |
| SLC29A1 | 7.35E–06 | 7.44E–03 | 1.25 | 2.38E–04 | 1.23 | 2.02E–05 | 1.27 | solute carrier family 29 (nucleoside transporters), member 1 |
| ARHGEF40 | 7.41E–06 | 7.44E–03 | 1.24 | 6.08E–05 | 1.25 | 8.71E–05 | 1.23 | Rho guanine nucleotide exchange factor (GEF) 40 |
| WDFY4 | 9.23E–06 | 8.85E–03 | –1.18 | 3.55E–04 | –1.16 | 1.94E–05 | –1.20 | WDFY family member 4 |
| SPNS3 | 1.08E–05 | 9.90E–03 | 1.13 | 7.31E–05 | 1.13 | 1.35E–04 | 1.12 | spinster homolog 3 (Drosophila) |
| SLC31A2 | 1.33E–05 | 1.13E–02 | 1.24 | 1.30E–03 | 1.19 | 8.34E–06 | 1.28 | solute carrier family 31 (copper transporters), member 2 |
| PLB1 | 1.34E–05 | 1.13E–02 | –1.19 | 2.32E–03 | –1.15 | 4.29E–06 | –1.24 | phospholipase B1 |
| MIR23A | 1.54E–05 | 1.25E–02 | 1.26 | 7.83E–05 | 1.28 | 2.30E–04 | 1.25 | microRNA 23a |
| SIGLEC8 | 1.76E–05 | 1.36E–02 | 1.21 | 9.58E–05 | 1.22 | 2.34E–04 | 1.20 | sialic acid binding Ig-like lectin 8 |
| PRSS33 | 1.80E–05 | 1.36E–02 | 1.16 | 8.45E–05 | 1.17 | 2.74E–04 | 1.15 | protease, serine, 33 |
| DNAJB5 | 1.95E–05 | 1.42E–02 | 1.19 | 5.26E–04 | 1.18 | 4.59E–05 | 1.21 | DnaJ (Hsp40) homolog, subfamily B, member 5 |
| CYSLTR2 | 2.27E–05 | 1.60E–02 | 1.35 | 3.98E–04 | 1.33 | 8.10E–05 | 1.37 | cysteinyl leukotriene receptor 2 |
| SLC5A3 | 2.65E–05 | 1.80E–02 | –1.18 | 9.81E–05 | –1.20 | 4.47E–04 | –1.17 | solute carrier family 5 (sodium/myo-inositol cotransporter), member 3 |
| PIGB | 2.99E–05 | 1.97E–02 | 1.27 | 1.43E–03 | 1.23 | 3.11E–05 | 1.31 | phosphatidylinositol glycan anchor biosynthesis, class B |
| RFX2 | 3.96E–05 | 2.49E–02 | 1.29 | 2.52E–04 | 1.30 | 3.35E–04 | 1.28 | regulatory factor X, 2 (influences HLA class II expression) |
| SULF2 | 4.02E–05 | 2.49E–02 | –1.19 | 1.84E–04 | –1.20 | 4.74E–04 | –1.18 | sulfatase 2 |
| CLDN10 | 4.94E–05 | 2.98E–02 | 1.17 | 5.65E–04 | 1.17 | 2.09E–04 | 1.18 | claudin 10 |
| KIAA0226L | 5.30E–05 | 3.10E–02 | –1.21 | 5.19E–04 | –1.20 | 2.57E–04 | –1.21 | KIAA0226-like |
| ECT2 | 6.01E–05 | 3.43E–02 | 1.19 | 1.60E–03 | 1.16 | 9.28E–05 | 1.21 | epithelial cell-transforming sequence 2 oncogene |
| TPPP3 | 6.21E–05 | 3.45E–02 | 1.25 | 1.94E–02 | 1.15 | 4.24E–06 | 1.35 | tubulin polymerization-promoting protein family member 3 |
| OLIG2 | 8.29E–05 | 4.37E–02 | 1.12 | 8.05E–05 | 1.15 | 3.32E–03 | 1.10 | oligodendrocyte lineage transcription factor 2 |
| SMPD3 | 1.10E–04 | 5.52E–02 | 1.27 | 1.80E–03 | 1.25 | 2.30E–04 | 1.30 | sphingomyelin phosphodiesterase 3, neutral membrane (neutral sphingomyelinase II) |
| ZNF532 | 1.23E–04 | 6.03E–02 | –1.10 | 2.79E–04 | –1.11 | 1.93E–03 | –1.09 | zinc finger protein 532 |
| DDX18P1 | 1.52E–04 | 7.26E–02 | –1.17 | 3.48E–04 | –1.19 | 2.18E–03 | –1.15 | DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 pseudogene 1 |
| EPHA4 | 1.55E–04 | 7.26E–02 | –1.14 | 1.11E–03 | –1.14 | 7.01E–04 | –1.14 | EPH receptor A4 |
| AOC2 | 1.61E–04 | 7.38E–02 | –1.17 | 1.39E–03 | –1.16 | 5.86E–04 | –1.17 | amine oxidase, copper containing 2 (retina-specific) |
| KIAA1324 | 1.65E–04 | 7.40E–02 | –1.25 | 4.61E–04 | –1.27 | 1.89E–03 | –1.22 | KIAA1324 |
| CD93 | 1.74E–04 | 7.42E–02 | –1.20 | 7.32E–04 | –1.21 | 1.30E–03 | –1.19 | CD93 molecule |
| DTNB | 1.74E–04 | 7.42E–02 | –1.08 | 2.12E–03 | –1.07 | 4.23E–04 | –1.08 | dystrobrevin, beta |
| AHCTF1 | 1.76E–04 | 7.42E–02 | –1.21 | 2.92E–03 | –1.19 | 3.01E–04 | –1.23 | AT hook containing transcription factor 1 |
| EMR4P | 1.83E–04 | 7.57E–02 | 1.26 | 3.75E–04 | 1.29 | 2.73E–03 | 1.22 | egf-like module containing, mucin-like, hormone receptor-like 4 pseudogene |
| CEBPE | 1.91E–04 | 7.75E–02 | 1.17 | 3.40E–04 | 1.19 | 3.21E–03 | 1.14 | CCAAT/enhancer binding protein (C/EBP), epsilon |
| EMR1 | 2.03E–04 | 8.08E–02 | 1.31 | 4.42E–03 | 1.27 | 2.38E–04 | 1.36 | egf-like module containing, mucin-like, hormone receptor-like 1 |
| FRRS1 | 2.15E–04 | 8.17E–02 | 1.23 | 2.66E–03 | 1.21 | 4.71E–04 | 1.24 | ferric-chelate reductase 1 |
| SLC23A2 | 2.15E–04 | 8.17E–02 | –1.15 | 6.24E–04 | –1.16 | 2.16E–03 | –1.13 | solute carrier family 23 (nucleobase transporters), member 2 |
| CYP4F3 | 2.17E–04 | 8.17E–02 | –1.18 | 2.29E–03 | –1.17 | 5.67E–04 | –1.19 | cytochrome P450, family 4, subfamily F, polypeptide 3 |
| ATG2A | 2.45E–04 | 9.06E–02 | –1.20 | 1.82E–03 | –1.19 | 8.90E–04 | –1.20 | autophagy related 2A |
| ARMC2 | 2.53E–04 | 9.17E–02 | 1.13 | 4.14E–03 | 1.12 | 3.79E–04 | 1.15 | armadillo repeat containing 2 |
| IFI6 | 2.61E–04 | 9.17E–02 | 1.29 | 1.86E–02 | 1.20 | 6.10E–05 | 1.38 | interferon, alpha-inducible protein 6 |
| P2RY2 | 2.61E–04 | 9.17E–02 | 1.16 | 2.53E–03 | 1.16 | 6.94E–04 | 1.17 | purinergic receptor P2Y, G-protein coupled, 2 |
| PACS1 | 2.70E–04 | 9.33E–02 | –1.14 | 1.07E–03 | –1.15 | 1.81E–03 | –1.14 | phosphofurin acidic cluster sorting protein 1 |
| PIK3R6 | 2.94E–04 | 9.84E–02 | 1.16 | 6.23E–03 | 1.14 | 3.04E–04 | 1.18 | phosphoinositide-3-kinase, regulatory subunit 6 |